Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas E Faries

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
Clinicoeconomics and Outcomes Research : CEOR|September 22, 2011
Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorderXianchen Liu, Yi Chen, Douglas E Faries
Statistics in Medicine|February 20, 2016
Estimating optimal treatment regimes via subgroup identification in randomized control trials and observational studiesHaoda Fu, Jin Zhou, Douglas E Faries
Pharmaceutical Statistics|October 13, 2012
The challenges of evaluating dose response in flexible-dose trials using marginal structural modelsIlya Lipkovich, Craig H Mallinckrodt, Douglas E Faries
Cost Effectiveness and Resource Allocation : C/E|May 29, 2009
Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study exampleDouglas E Faries, Allen W Nyhuis, Haya Ascher-Svanum
International Clinical Psychopharmacology|August 14, 2010
Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorderXianchen Liu, Steve Gelwicks, Douglas E Faries, et al.
Journal of Biopharmaceutical Statistics|March 11, 2017
Evaluating different strategies for estimating treatment effects in observational studiesAnthony J Zagar, Zbigniew Kadziola, Ilya Lipkovich, et al.
Journal of Medical Economics|September 7, 2011
Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetineZhanglin Cui, Douglas E Faries, Yang Zhao, et al.
Journal of Medical Economics|October 22, 2011
Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspectiveZhanglin Cui, Douglas E Faries, Steven Gelwicks, et al.
Psychiatric Services (Washington, D.C.)|October 5, 2011
Predicting psychiatric hospital admission among adults with schizophreniaMark Olfson, Haya Ascher-Svanum, Douglas E Faries, et al.
Biometrics|March 19, 2016
Propensity score matching and subclassification in observational studies with multi-level treatmentsShu Yang, Guido W Imbens, Zhanglin Cui, et al.
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
Clinicoeconomics and Outcomes Research : CEOR|September 22, 2011
Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorderXianchen Liu, Yi Chen, Douglas E Faries
Statistics in Medicine|February 20, 2016
Estimating optimal treatment regimes via subgroup identification in randomized control trials and observational studiesHaoda Fu, Jin Zhou, Douglas E Faries
Pharmaceutical Statistics|October 13, 2012
The challenges of evaluating dose response in flexible-dose trials using marginal structural modelsIlya Lipkovich, Craig H Mallinckrodt, Douglas E Faries
Cost Effectiveness and Resource Allocation : C/E|May 29, 2009
Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study exampleDouglas E Faries, Allen W Nyhuis, Haya Ascher-Svanum
International Clinical Psychopharmacology|August 14, 2010
Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorderXianchen Liu, Steve Gelwicks, Douglas E Faries, et al.
Journal of Biopharmaceutical Statistics|March 11, 2017
Evaluating different strategies for estimating treatment effects in observational studiesAnthony J Zagar, Zbigniew Kadziola, Ilya Lipkovich, et al.
Journal of Medical Economics|September 7, 2011
Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetineZhanglin Cui, Douglas E Faries, Yang Zhao, et al.
Journal of Medical Economics|October 22, 2011
Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspectiveZhanglin Cui, Douglas E Faries, Steven Gelwicks, et al.
Psychiatric Services (Washington, D.C.)|October 5, 2011
Predicting psychiatric hospital admission among adults with schizophreniaMark Olfson, Haya Ascher-Svanum, Douglas E Faries, et al.
Biometrics|March 19, 2016
Propensity score matching and subclassification in observational studies with multi-level treatmentsShu Yang, Guido W Imbens, Zhanglin Cui, et al.
Pageof 8